Adaptin Bio, Inc. (APTN)
APTN is quoted over the counter, not listed on an exchange. Adaptin Bio, Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Profile
| Field | Value |
|---|---|
| Ticker | APTN, quoted over the counter |
| SEC CIK | 0001938571 |
| OTC Markets tier | OTCQB (price source, 2026-11-13) |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Business address | Charlotte, NC |
| Incorporated in | DE |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These matters raise substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-11-13 |
| Cash and burn | $670K cash; operating cash flow -$630K a quarter. | Report 2026-06-30 |
| Shares outstanding | 9,261,601 (2026-11-12); 8,455,829 a year earlier; 5,000,000 three years earlier. | Cover page 2026-11-12 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | WithumSmith+Brown, PC, East Brunswick, New Jersey, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-02-18 |
| Late filings, 12 months | 1 NT notice | NT 10-K 2026-04-01 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$1.2M | -$450K | $670K | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | Not filed | -$1.1M | -$596K | $301K | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q4 2025 2025-12-31 | Not filed | -$1.4M | -$703K | $459K | No debt tags | Needs four quarters | 10-K 2026-04-01 |
| Q3 2025 2025-09-30 | Not filed | -$1.7M | -$772K | $579K | No debt tags | Needs four quarters | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | Not filed | -$1.5M | -$1.0M | $1.4M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | Not filed | -$603K | -$2.3M | $2.4M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q4 2024 2024-12-31 | Not filed | -$857K | $113K | $34K | $1.5M | Needs four quarters | 10-K 2026-04-01 |
| Q3 2024 2024-09-30 | Not filed | -$1.1M | -$468K | $115K | $138K | Needs four quarters | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-09-10 |
| Latest annual report | 10-K/A | 2026-06-12 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-08-25 |
Source: SEC EDGAR submissions feed, 76 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier